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Abstract 
Objectives. I investigated gay and bisexual men’s willingness to self-administer an anal cancer 
screening test at home. 
Methods. I reviewed the current literature on acceptability of cytological anal cancer screening 
tests among gay and bisexual men by searching three databases (MEDLINE, Web of Science, 
and PsychINFO) and present a qualitative synthesis of the literature. I then performed a 
secondary data analysis of two national, online surveys of gay and bisexual men: Study I in 2009 
with men ages 20-59 (n=306) and Study II in 2013 with men ages 18-26 (n=428).  I used logistic 
regression to identify bivariate correlates of willingness to self-administer an anal cancer 
screening test for both studies and scompared the results. 
Results. Most men were willing to self-administer an anal cancer screening test (78% Study I; 
67% Study II), similar to the findings of the most recent studies of physician-collected tests. In 
Study I, willingness was higher among men who trusted anal Paps to find treatable cancer 
(adjusted odds ratio [aOR]=1.47; 95% CI 1.04, 2.09) and who believed that men who have sex 
with men should be screened for anal cancer between one and three years vs. other intervals 
(aOR=2.19; 95% CI 1.17, 4.10). In Study II, willingness was higher among men who perceived 
greater likelihood of anal cancer (aOR=1.57; 95% CI 1.12, 2.20). Their most common concerns 
were not performing the test correctly and inaccuracy of results. 
Conclusions. Many gay and bisexual men were willing to self-administer anal cancer screening 
tests at home. If routine screening is warranted, self-collected home testing could improve 
participation. 
 
Acceptability of Cytological Anal Cancer Screening Among Gay and Bisexual Men – A 
Review of the Literature 
 
Introduction 
For the average man in the United States anal cancer is a rare threat—affecting fewer 
than two men per 100,000 per year.1 This despite the fact that there has been an almost constant 
increase in incidence over the past three decades (annual percent change 3 - 4%).2,3 Certain 
subpopulations, such as gay and bisexual men, suffer from a much greater burden of disease, 
which may account for some of the increase in incidence.4 The incidence of anal cancer among 
HIV-negative men who have sex with men (MSM) is approximately 5 cases/100,000 men-years. 
For MSM living with HIV/AIDs, the incidence of anal cancer is estimated to be between 50 and 
130 cases /100,000 men-years depending on whether one uses data from cancer registries or 
cohort studies.5-7 
Similar to cervical cancer, the majority of anal cancer cases are associated with infection 
by human papillomavirus (HPV), specifically high-risk types 16 or 18.8,9 Infection with these 
high-risk subtypes leads to dysplastic changes that can ultimately result in invasive cancer.10,11 
The prevalence of HPV infection and dysplastic lesions does not decrease with age in gay and 
bisexual men, in contrast to what is observed in women.12,13 In fact, a recent study confirmed that 
the risk of anal cancer among gay and bisexual men increases with age.7  Prevalence of high-risk 
HPV types is even higher for MSM living with HIV/AIDS compared to HIV-negative MSM, 
despite use of antiretroviral therapy.6,14 Other risk factors (aside from HIV) for persistent HPV 
infection, subsequent dysplasia, and cancer include the following: having multiple sexual 
partners, particularly receptive anal sex partners;6,12-15 smoking;8,15-17 and low CD4 count.17,18 
Anal cytological screening and treatment of dysplastic lesions have been proposed as a 
way of reducing the burden of anal cancer.19,20 A recent meta-analysis showed anal cytology has 
sensitivity and specificity similar to cervical Pap testing (90% and 33%, respectively).21 No 
studies have been done to show that routine screening improves mortality rates or other patient-
centered outcomes.22,23 A clinical trial to determine the efficacy of screening is just now 
beginning recruitment, and it will be several years before the results are published 
(NCT02135419).  
Despite the lack of health outcomes data, some health professionals and organizations 
have begun recommending screening.23 The Infectious Diseases Society of America (IDSA) 
recently updated their primary care guidelines to recommend anal Pap testing for HIV-infected 
MSM due to the high risk of anal cancer in that population.24 The new recommendation will 
likely increase the rate of anal cancer screening in HIV-positive MSM. For this reason, it is 
important to understand the acceptability of screening among these men. Such knowledge may 
be invaluable for public health efforts to maximize prevention efforts’ reach if future trials 
demonstrate the efficacy of screening.  
To my knowledge, only one previous review has examined the literature in this area, but 
the study used a narrative rather than systematic approach, had a broader focus on the general 
psychological aspects of anal cancer screening, and did not include some more recent articles.25 
The goal of this review, therefore, is to systematically assess what is currently known about gay 
and bisexual men’s acceptance of anal cancer screening.  
 
Methods 
Literature Search Strategy 
I searched MEDLINE, Web of Science, and PsychINFO for English-language, human-
only studies published from database inception through March 6, 2014.  I identified additional 
studies by manually searching the references lists of included studies. Searches combined 
multiple terms for sexual minority men, anal cancer and dysplasia, and screening or prevention.  
The search was limited to studies reporting outcomes of the acceptance of anal cancer 
cytological screening (i.e., anal Pap) or willingness or intent to undergo screening among gay 
and/or bisexual men or MSM. Inclusion and exclusion criteria are summarized in Table 1 
Table 1. Inclusion/exclusion criteria for studies assessing acceptance of anal cancer screening 
among men. 
Category 
Criteria 
Inclusion Exclusion 
Population • Adult men who identify as anything 
other than heterosexual or who 
report having sex with men 
• All other populations 
Interventions • Anal Pap exam (anal cytology) 
 
• Digital Rectal Exam (DRE) 
• HPV serology 
• Anal HPV testing 
• High-resolution anoscopy 
(HRA) +/- biopsy 
Outcomes • Willingness or intent to undergo anal 
cancer screening 
• Beliefs related to anal cancer 
screening 
• Acceptance of anal cancer screening 
• Epidemiology, natural history, 
or management of HPV or 
dysplasia 
• Anal Pap test characteristics 
Time period Studies published through March 6, 2014  
Settings Any setting (clinic, community venue, home-testing) 
Study Design • Cross-sectional studies 
• Cohort studies 
• Case-control studies 
• RCTs 
• Reviews 
• Guidelines 
• Meta-analyses 
• Cost-effectiveness analyses 
• Case reports 
Public language • English • All other languages 
 
I reviewed abstracts to determine if studies met the inclusion and exclusion criteria. If it 
was unclear whether a study met criteria, the abstract was marked as “included.” I reviewed the 
full text article of all included abstracts against the criteria outlined in Table 1. For studies 
meeting inclusion criteria, I abstracted relevant data on characteristics of included trials and 
relevant outcomes using a pre-defined form. Specifically, I was interested in the study design, 
the sample population, how the study measured acceptance of screening or intent to screen, the 
overall level of acceptance or intent, and statistically significant multivariate correlates of 
acceptance or intent. 
 
Quality Assessment of Included Studies 
I evaluated the quality of studies using predefined criteria, based on the Methods for the 
development of NICE public health guidance, 3rd edition.26 I assessed whether the studies 
adequately described their source and sample population, selection of the sample population, 
measurement of the primary outcome (e.g. acceptability of screening) and covariates, statistical 
analyses, overall internal validity of the findings, and the generalizability of those findings to 
other gay and bisexual men. I assessed risk of measurement bias based only on how the study 
measured screening acceptability and its covariates, not on other outcomes reported in the trial. I 
rated each study as being of good, fair, or poor quality. Poor quality studies are those that I judge 
to have one or more critical flaws, such as a failure to adequately or properly measure screening 
acceptability (e.g,, measurement bias) or failure to measure important covariates that may affect 
screening acceptability. 
Finally, I summarize and qualitatively synthesize the results of the included studies, 
focusing on overall acceptance of screening or intent to screen, and the multivariate correlates of 
acceptance or intent to undergo screening. 
 
 
 
 
 Results  
 
Figure 1. Flowchart of study selection process 
 
The literature search resulted in 553 unique articles. Figure 1 summarizes results of the 
search and the study selection process. Ten articles met all criteria and were included in the 
review. Table 2 summarizes the study design and sample characteristics of each study, as well as 
how authors measured “acceptance of screening.” In general, across included trials, there was 
heterogeneity in study design and methods used to measure acceptance of anal Pap screening. 
These issues are discussed in more detail in the following sections. 
 
Table 2. Overview of study design and quality 
 Design Study Population Sample Description Acceptability Measure Quality 
Screening behavior 
D’Souza et al., 201327 
   (United States) 
Cohort study Multicenter AIDS Cohort Study 
   (MACS) participants 
Baltimore, Chicago, Pittsburgh, 
   Los Angeles 
Enrolled all men with a MACS  
   visit during study period 
2010-2011 
 
n = 1742 (78% of cohort) 
- unknown % MSM 
- 47% HIV+ 
- med. age 55y 
- 67% White, 20% Black 
- med. income $40-49,000 
- 23% previous screening 
Acceptance of free,  
   physician-collected  
   Pap 
Good 
Gilbert et al., 201128 
   (Canada) 
Cohort study Men at MSM-frequented  
   venues in Vancouver, British  
   Columbia 
Randomized time-space  
   sampling 
2008-2009 
n = 766 
- 90% gay or bisexual 
- approx 16% HIV+  
- 56% age 25-44y 
- 73% European or North 
American ethnic origin 
- 79% income >$20,000  
- approx 24% previous screening 
 
Acceptance of free, self- 
   collected Pap 
Fair 
Goodall & Clutterbuck,    
201229 
   (UK) 
Retrospective case- 
   control study 
Single HIV Clinic in Edinburgh 
Consecutive sampling –  
   included all HIV+ MSM  
   attending clinic 
2006-2007 
n = 285 (215 offered screening) 
- 100% MSM 
- 100% HIV+ 
- mean age 39y 
- unknown ethnic groups, 97% 
British or White non-British 
- unknown income, previous 
screening 
 
Acceptance of  
   physician-collected  
   Pap 
Poor 
Truesdale & Goldstone, 
201030 
   (United States) 
 
 
 
 
Retrospective cohort Men referred for screening at  
   single surgical clinic with  
   abnormal anal cytology 
Unknown recruitment  
   procedure, possibly  
   convenience sample? 
2007-2008 
n = 195  
- 100% MSM 
- 49% HIV+ 
- mean age 44y 
- 78% White, 9% Black 
- unknown income 
- 100% screened at least once 
Compliance with  
   follow-up  
   recommendations for 
   physician-collected  
   Pap testing 
Poor 
Willingness or intent to get Pap 
D’Souza et al., 200831 
   (United States) 
Cross-sectional 
    survey 
MACS participants 
Baltimore, Chicago, Pittsburgh,  
   Los Angeles 
Surveyed entire cohort 
2005 
n = 1917 
- approx 93% MSM 
- 47% HIV+ 
- med. age 48y 
- 63% White, 26% Black 
- med. income $35,000 
- 11% previous screening 
Intent to get anal  
   screening in next 6  
   months 
Fair 
 Reed et al., 201032 
   (United States) 
Cross-sectional  
   survey 
National probability sample of  
   self-identified gay and  
   bisexual men 
2009 
n = 306 
- 100% self-identified as gay or 
bisexual 
-17% HIV+ 
- mean age 46y 
- 81% non-Hispanic White, 5% 
non-Hispanic Black 
- 60% income ≥$60,000 
-14% previous screening 
Willingness to get  
   physician-collected 
   anal Pap 
Good 
Willingness to repeat Pap after collection 
Davis, Goldstone, & 
Chen, 201333 
   (United States) 
Cohort study 
 
Men and women referred for 
   screening at single clinic  
   specializing in HPV-related, 
   anorectal disease 
Unknown recruitment  
   procedure 
2010 
 
-292 people 
-97% male, “mostly MSM” 
-45% HIV+ 
- mean age 43 
- unknown ethnic groups 
-63% previous screening 
Willingness to repeat Pap 
after physician-collected 
test 
Poor 
Vajdic et al., 200534 
   (Australia) 
Cohort study Men presenting or referred to  
   gay health clinic or  
   community-based HIV clinic 
Consecutive sampling 
Unknown time period 
n = 151 
- 100% MSM 
- 64% HIV+ 
- mean age 45y 
- unknown ethnic groups, income 
- 43% “previous medical 
treatment of anus” 
Willingness to repeat 
   Pap after physician- 
   collected test 
Poor 
Other 
Newman et al., 200835 
   (United States) 
Qualitative study 
 
Four semi-structured,  
   open-ended focus  
   groups  
Health care advocates for gay  
   men and MSM in Los  
   Angeles 
Purposive sampling 
Unknown year 
 
n = 19 
- 16 men, 3 women 
- several were gay men of color 
Barriers and facilitators  
   of anal cancer  
   screening 
Fair 
Botes et al., 201136 
   (Australia) 
Cohort study Unknown source population 
Consecutive recruitment 
2008-2009 
n = 263 
- 100% MSM 
- 100% HIV+ 
- med. age 50 
- unknown ethnic groups, income, 
previous screening 
Acceptability of Pap  
   after self-collected test 
Poor 
MSM = men who have sex with men  MACS = Multicenter AIDS Cohort Study
 Characteristics of Included Studies 
Sample Populations. Among the 9 quantitative studies, sample sizes ranged from 151 to 
1917 men; one study (n = 19) assessed acceptability of screening via focus groups.35 The most 
common source populations were individual clinics; four studies reported data from two surgical 
clinics, two HIV clinics, and one primary care clinic specializing in gay men’s health (Table 2). 
Two studies surveyed men living in large metropolitan areas who were participants in the 
Multicenter AIDS Cohort Study (MACS).27,31 Only one study used a national probability 
sample.32 Almost all studies recruited samples that were mostly or entirely MSM; though, only 
one defined criteria for inclusion as MSM,28 and one study used self-identified sexual orientation 
rather than MSM status.32 The proportion of participants who were HIV-positive varied from 
16% to 100% of the sample, but most studies (5/9 quantitative studies) had approximately even 
numbers of HIV-positive and –negative men. All quantitative studies included at least some 
HIV-positive men. The mean or median age of all study samples ranged from 39-55. Most 
studies provided little additional detail on the study populations or recruitment procedure aside 
from the characteristics summarized above. 
Study Quality. Five of the included studies were of good or fair quality, and the 
remaining were rated poor quality (Appendix 1). Among the trials rated as poor quality, the most 
common methodological bias was inadequate description of the study population, and therefore 
insufficient data to judge the applicability of the results (6/10 studies). Other common 
methodological flaws included the following: 1) insufficient description of the measurement 
instruments (4/9 quantitative studies); 2) failure to measure potentially confounding factors 
associated with acceptability (3/9); and 3) inadequate statistical analysis, specifically not using 
multivariate modeling to control for confounding among the covariates (5/9).  
Measurement of Anal Pap Screening Acceptability. There was considerable heterogeneity 
in study design and how authors measured and defined acceptance of anal Pap screening. Four 
studies, including two prospective cohorts, one retrospective cohort, and one retrospective case-
control study, examined actual screening behaviors of men offered or referred for Pap 
screening.27-30 Two cross-sectional national surveys measured willingness or intent to get a Pap 
in the future.31,32 Two cohort studies assessed participants’ willingness to repeat screening after 
undergoing Pap testing.33,34 I also included one cohort study that assessed acceptability of the 
Pap after a self-collected test and a qualitative study identifying barriers and facilitators to anal 
cancer screening.35,36 For the remainder of the review, I will refer to the outcome measures as 
“acceptability” except where it is necessary to differentiate between the studies. 
Acceptability of Anal Pap Screening. Reported rates anal Pap acceptability varied 
depending on several factors: 1) the context in which the test was delivered 2) the cost of testing, 
and if the test was physician- or self-collected. When the Pap was offered for free, acceptability 
was high (83%-85%).27,32 Acceptability was lower when the Pap was not explicitly free (12-
62%)29,31,32 or when it was self-collected in a public facility (35%).28 When measured after men 
received an anal Pap, acceptability of the test was high and most men were willing to repeat the 
test in the future.33,34,36 
Factors Associated with Acceptability. Six of the nine quantitative studies measured 
psychosocial and/or demographic variables associated with acceptance of screening or 
willingness to screen. Only four created multivariate models of acceptance (Table 3). Multiple 
studies found that people who worried more about anal cancer or had a history of a previous Pap 
were more likely to be accepting of the test. D’Souza et al. (2008) found that having more sexual 
partners and being HIV-positive were associated with greater acceptability,31 but other studies 
showed no statistically significant association. Similarly, Reed et al. found that people with 
higher levels of education were less accepting of anal Paps,32 but D’Souza et al. (2013) found no 
significant association.27  Studies found opposite associations for both race and income on 
measures of acceptability. In D’Souza et al. (2008), Black participants in the Multicenter AIDS 
Cohort Study had a greater odds of “intent to be screened” in the next 6 months compared to 
White men. In another study of MACS participants 5 years later, Black participants had more 
than twice the odds of declining an offered Pap compared to White men.27 Men with low income 
(<$20,000/year) in Gilbert et al. were more likely to accept a free self-collected Pap,28 but in 
Reed et al., men with a higher income (≥$60,000/year) were more likely to say they were willing 
to get a Pap test that cost $150.32 
 The one qualitative study exploring MSM’s beliefs associated with anal cancer screening 
identified six categories of barriers to screening: lack of awareness of screening, the potential for 
stigma to be associated with screening, psychological and physical discomfort, the idea of the 
anus as a private area, overriding concern for HIV, and a general reluctance of men to seek 
health care.35 Focus group participants also suggested three possible facilitating factors: 
increasing the number and diversity of screening sites (including home testing), making changes 
to the health care system (such as physicians routinely recommending screening), and education 
campaigns to increase awareness. 
 
Discussion 
 I found ten studies that explored the acceptability of anal cancer cytological screening 
among gay and bisexual men. To my knowledge, this is the first systematic review specifically 
assessing acceptability of screening in this high-risk population, and the factors that predict 
acceptance. An earlier review focused on the broader psychosocial aspects of anal cancer 
screening without regard to a specific population and included three of the studies reviewed 
here.25 
 At first glance, it appears that the fair or good quality studies included in this review 
found very different degrees of acceptability among gay and bisexual men. Three studies 
reported that only 29-35% of men were willing to or intended to be screened,28,31,32 whereas 85% 
of men in the most recent study accepted a Pap test.27 Of note, the two studies with the most 
widely divergent results, D’Souza et al. 2008 and 2013, used essentially the same samples: 
participants in the Multicenter AIDS Cohort Study.27,31 
 Differences in the design and characteristics of the sample populations of these studies 
may be responsible for the heterogeneous results. Awareness and prior utilization of anal Pap 
testing were found to be as different between studies as acceptability. In the two earlier studies, 
D’Souza et al. (2008) and Reed et al., only 11 and 14% of men, respectively, had undergone a 
Pap prior to the study.31,32 Approximately 25% of men in both of the later published studies had 
previously been screened.27,28 Furthermore, Reed et al. reported that only 23% of the men in their 
sample had heard of Pap testing,32 but 65% of men surveyed by D’Souza et al. (2013) reported 
being familiar with the test.27 Since it appears likely that having had a Pap test predicts 
acceptability, it is not surprising that the study with the highest Pap awareness and proportion of 
men with a history of Paps also reported the highest acceptability. 
 Two of the studies, D’Souza et al. (2008) and Reed et al., measured willingness or intent 
to be screened,31,32 and the other two studies, Gilbert et al. and D’Souza et al. (2013), measured 
men’s behavior when offered a free screening test and found higher acceptability.27,28 This runs 
counter to previous studies that have shown measuring intention generally overestimates actual 
behavior regarding cancer screening and other preventive health choices.37-39 Some of this 
difference may be due to participants’ explicit or implicit consideration of cost. The behavioral 
studies offered the tests for no cost to participants. D’Souza et al. (2008) asked about men’s 
likelihood to be screened in the near future, without explicitly telling them to consider cost.31 
Reed et al. measured acceptability of a Pap test that cost $150 out of pocket (the primary 
outcome) and one that was free.32 When the test was free, 83% of men said they were willing to 
be screened—almost the exact number of men who accepted the free test in D’Souza et al. 
(2013).27 This suggests that cost considerations are an important part of gay and bisexual men’s 
decision-making process regarding anal cancer screening. 
 Only one study in this review, Gilbert et al., assessed the acceptability of self-collected 
anal Pap tests.28 Based on other literature on self-collected tests for sexually transmitted diseases 
among MSM, I would expect to see high rates of acceptance.40-42 The anomalously low 
acceptability reported by Gilbert et al., despite their high proportion of men with previous Pap 
screening and the offer of a free test, is likely due to differences in setting. This study was 
conducted within a community-based setting; participants were approached in MSM-frequented 
venues in Vancouver and asked to self-collect an anal Pap in the venue’s bathroom. It is possible 
that a self-collected test performed at home would be more appealing to men, as suggested by the 
focus groups in Newman et al.35 
 I found numerous differences in the magnitude, direction, and statistical significance of 
the effects of multivariate correlates on men’s acceptability of anal Pap testing. Two potentially 
modifiable factors studies agreed were associated with acceptability are worry about anal cancer 
and a history of previous Pap testing. Worry, considered a component of risk perception or 
affective response to risk, is well established as a predictor of preventive health behavior.43,44 
Studies have also shown that previous use of cancer screening tests is associated with greater use 
in the future .37,45,46 
 Different studies in this review reported increased acceptability associated with less 
education, more sexual partners, and being HIV-positive; however, at least one other included 
study failed to find a statistically significant association for each one. It is possible that they were 
simply underpowered to detect the association, but more research is needed to confirm these 
variables as correlates of anal cancer screening acceptability.  
 The conflicting results regarding income found by Gilbert et al. and Reed et al. may be 
due to the incentives men received to participate in the studies.28,32 All men received equal 
compensation in the Reed study. Although the men in the Gilbert study who answered the survey 
portion all received the same amount of money, those that agreed to use a self-collected anal 
screening test received an additional CDN$10. The authors hypothesize that this could be why 
men with incomes <$20,000 were more likely to accept the Pap. 
 D’Souza et al. 2008 and 2013 finding significant associations with acceptability in 
opposite directions for Black race is more difficult to explain.27,31 These studies surveyed the 
MACS cohort at two different time points but had very different results in terms of overall 
acceptability and covariates. It is possible that the difference is due to some change in the Black 
participants over time, but a more likely explanation may be that the difference is due to how 
each study asked men about screening acceptability. The earlier study asked men about the 
chance they would be screened in the future, and the latter offered men an actual anal Pap.  
Predictive factors for intent and behavior are not always the same,37 and it is possible that Black 
men overestimate the actual chances they will use anal cancer screening more than White men. 
Limitations of the Literature 
The current body of literature on gay and bisexual’s men acceptability of anal cancer 
cytological screening has significant limitations. Only three good quality, multicenter or 
nationally representative studies have explored this topic, and they had mixed results. Two of 
those studies measured men’s intent to be screened with a cross-sectional survey, rather than 
assessing actual behavior. They may not represent what could be expected if routine screening 
was recommended for MSM. The majority of studies included in this review had samples limited 
to single clinics and many failed to adequately describe their clinic populations. This makes it 
difficult to determine the applicability of their findings to other men.  
Limitations of This Review 
The scope of this review was limited to only three databases and only articles published 
in English. A more thorough search that included additional databases and the grey literature 
may find other relevant studies. Furthermore, only a single reviewer read the abstracts and full 
text articles to determine inclusion. This may introduce some error.  
Future Directions 
Now that the IDSA is recommending screening for some high-risk individuals, future 
studies should focus on determining screening uptake, rather than intent to be screened, among 
men referred for screening and the sociodemographic and psychological factors that predict use 
of screening. Although all MSM have an increase chance of developing anal cancer, behavioral 
research should focus on MSM living with HIV due to their uniquely high risk and the 
uncertainty regarding screening efficacy, especially in the HIV-negative population. Future 
research should also attempt to confirm the relationship of potential covariates to screening 
behavior that previous studies have disagreed upon, such as number of partners and HIV status.  
Lastly, more work should be done to sample MSM populations in a way that allows bisexual 
men to be assessed as a distinct group. Bisexual men suffer from a number of health concerns 
and health access disparities independent of gay men, but most of studies in this review (and in 
LGBT research generally) combined the two populations due to small samples.47 
Conclusion 
 In conclusion, the literature suggests that anal cancer cytological screening is acceptable 
to gay and bisexual men when offered at no charge or as part of a study but may be less 
acceptable when real-world costs are considered. Efforts to improve screening uptake (if 
screening is proven to be efficacious in preventing anal cancer) should target men with no prior 
history of screening and concentrate on informing men at the highest risk for anal cancer about 
the disease and prevention options. 
Table 3. Summary of results for studies that reported multivariate correlates 
Author 
Year (n) Primary Outcome 
Multivariate Correlates of Acceptance, OR (95% CI) 
Racea Income Education # Partners Worry about 
anal cancer Previous Pap HIV+ 
D’Souza et al. 
   2008 (1917)31 
12% likely to be 
screened in next 6 mo 
17% possibly will be 
screened 
1.42 
(1.06, 1.90) 
-- -- 1.8 (1.4, 2.5)b 2.9 (2.2, 3.9)c 
 
4.7 (3.3, 6.7)d 
1.9 (1.4, 2.6) 1.9 (1.5, 2.5) 
Gilbert et al. 
   2011 (766)28 
35% accepted Pap -- 2.00 
(1.24, 3.22)e 
-- n.s. -- 1.67 
(1.05, 2.67) 
-- 
Reed et al. 
   2010 (306)32 
31% willing to get Pap  
 
-- 2.17 
(1.18, 3.98)f 
0.54 
(0.32, 0.89)g 
-- 1.70 
(1.06, 2.72)h 
n.s. n.s. 
D’Souza et al. 
2013 (1742)27 
15% declined Pap 2.15 (1.18, 3.9) n.s. n.s. -- -- -- n.s. 
n.s. = not statistically significant 
a Black vs White 
b 
≥3 receptive anal male sex partners in past 6 months vs none 
c Moderately concerned vs not concerned  
d Very concerned vs not concerned 
e
 <$20,000 vs >$20,000 per year 
f
  ≥$60,000 vs <$60,000 per year 
g Greater than vs less than high school education 
h 4-point scale, from “not at all” (coded as 1) to “quite a lot” (coded as 4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Appendix 1. Quality Assessment of Studies of Anal Cancer Screening Acceptability Among Men Who Have Sex With Men 
First 
author, 
year 
Eligibility 
criteria 
clearly 
described? 
Subjects 
representative 
of the overall 
source 
population? 
 
Generalizability 
to other 
gay/bisexual/ 
MSM pop.? 
(high/moderate/
low) 
Measured 
covariates 
based on a 
theoretical 
model or prior 
research? 
Outcome 
measures 
valid and 
reliable? 
Created 
multivariate model 
of covariate to 
adjust for 
confounding? 
Quality rating 
 
(good/fair/ 
poor) 
Comments 
D’Souza et 
al, 201327 
Yes Somewhat Moderate Yes Yes Yes Good Men offered Pap more likely to be White, have 
a college degree, have income >$40,000, 
have 0 receptive sex partners in past 6 mo. 
than those not offered Pap. 
 
MACS cohort only from 4 large urban centers. 
Pap was offered free – likely would not be in 
real world setting. 
Outcome was acceptance of Pap offer 
Reed et al., 
201032 
Yes Yes Moderate to 
High 
Yes Yes Yes Good National probability sample, but participants 
were mostly high-income and White and self-
identified as gay or bisexual 
 
Collapsed 5-point Likert response for 
willingness into dichotomous outcome 
Performed 2 rounds of pretesting prior to 
study start 
 
D’Souza et 
al, 200831 
Yes Yes Moderate Yes Unclear Yes Fair Included all men enrolled in Multicenter AIDS 
Cohort Study, which has been described in 
detail in previous articles. 
Men only came from 4 large urban centers 
Question used to measure intent to seek 
screening for anal cancer also asked about 
screening for anal warts and other “anal 
health problem[s].” 
This may overestimate actual cancer 
screening intent. 
First 
author, 
year 
Eligibility 
criteria 
clearly 
described? 
Subjects 
representative 
of the overall 
source 
population? 
 
Generalizability 
to other 
gay/bisexual/ 
MSM pop.? 
(high/moderate/
low) 
Measured 
covariates 
based on a 
theoretical 
model or prior 
research? 
Outcome 
measures 
valid and 
reliable? 
Created 
multivariate model 
of covariate to 
adjust for 
confounding? 
Quality rating 
 
(good/fair/ 
poor) 
Comments 
Gilbert et 
al., 201128 
Yes Yes Moderate No Yes Yes Fair Source population were men attending MSM-
frequented venues – likely not representative 
of men who do not attend such venues. 
 
Did not include several important covariates in 
multivariate model: orientation, smoking 
status, HIV status – potentially due to concern 
of colinearity with venue-type 
 
Outcome was acceptance of Pap offer 
Newman et 
al., 200835 
No Unclear Low N/A N/A N/A Fair Qualitative study. 
 
Focus group participants were primarily health 
care advocates rather than gay or bisexual or 
MSM patients 
Botes et al., 
201136 
No 
 
 
Unclear 
 
 
Unclear No No No Poor Did not describe source or sample population. 
Survey response options not mutually 
exclusive. 
Did not define “acceptance.” 
No bivariate or multivariate analysis of 
covariates. 
Covariates did not include any demographic 
or psychological variables 
Reported correlation coefficients rather than 
ORs. 
Davis et al., 
201333 
No Unclear Unclear N/A Unclear No Poor Did not describe recruitment procedure. 
Did not describe source or sample population. 
Did not measure any covariates. 
Exposure to multiple screening modalities at 
same visit (digital rectal exam, anoscopy) may 
confound outcome. 
Outcome was whether discomfort from Pap 
would prevent from repeating. 
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author, 
year 
Eligibility 
criteria 
clearly 
described? 
Subjects 
representative 
of the overall 
source 
population? 
 
Generalizability 
to other 
gay/bisexual/ 
MSM pop.? 
(high/moderate/
low) 
Measured 
covariates 
based on a 
theoretical 
model or prior 
research? 
Outcome 
measures 
valid and 
reliable? 
Created 
multivariate model 
of covariate to 
adjust for 
confounding? 
Quality rating 
 
(good/fair/ 
poor) 
Comments 
Goodall & 
Clutterbuck, 
201229 
Yes Unclear Low No Yes No Poor Sample included all HIV+ MSM at single clinic 
over one year 
Did not say why some patients (75%) were 
offered screening and others were not 
 
Outcome was acceptance of Pap offer. 
Reported percentages and p-values, not ORs 
– no multivariate analysis 
Truesdale & 
Goldstone, 
201030 
Yes Unclear Low Yes Yes No Poor Unknown recruitment procedure. 
 
12% response rate for contacted lost to follow-
up patients 
Results represent a single clinic, mostly White 
and well-educated. 
 
No multivariate analysis. 
 
 
Vajdic et al., 
200534 
Yes Unclear Low N/A Unclear No Poor Consecutive sampling of men from gay health 
clinic and HIV clinic – unlikely to be 
generalizable 
 
Did not measure any covariates of 
preparedness to repeat Pap test. 
 
Reported acceptance rating (5-point Likert 
scale) as mean and range – limited ability to 
interpret results 
 
No comparisons made of acceptance based 
on different covariates other than blind vs. 
anoscope-guided sampling 
Gay and Bisexual Men’s Willingness to Use a Self-Collected Anal Cancer Screening Test 
 
Introduction 
Incidence of common cancers affecting men in the United States (prostate, lung, and 
colorectal cancer) have declined over the past decade.48 Anal cancer incidence, however, has 
increased over the past three decades, and currently 1.5 men per 100,000 are affected per 
year.48,49 This increase is attributable, at least in part, to high incidence rates among men who 
have sex with men (MSM; ~5 men per 100,000 per year).49 Rates are even higher among MSM 
living with HIV/AIDS, with recent estimates ranging from 65 to 131 men per 100,000 per 
year.7,50  
 The majority (>70%) of cases of anal cancer are associated with human papillomavirus 
(HPV) infection, specifically with high-risk type 16 or 18.51 Risk factors for new or persistent 
anal HPV infections, as well as for anal cancer, include receptive anal intercourse, having 
multiple sexual partners, and smoking.8,12,52-55 These risk factors may explain why high-risk HPV 
types are common in HIV-negative and HIV-positive MSM (12.5% and 35.4%, respectively, for 
type 16).50,56,57 
 Anal cytological screening and treatment of dysplastic lesions could represent an 
important strategy for preventing anal cancer.19,20 Routine cervical Papanicolaou (Pap) testing 
has resulted in a dramatic decrease in the incidence of invasive cervical cancer in women over 
the last 50 years.58 It is possible that anal cancer screening could have similar effects for MSM, 
given the similarities between cervical and anal cancers and studies showing anal Pap tests have 
similar accuracy to cervical Paps.21 No studies have been conducted, though, to determine anal 
cancer screening’s effect on mortality or other patient-centered outcomes.59 Despite this 
uncertainty, some clinicians are now recommending high-risk men be screened for anal cancer 
because of the high incidence of anal cancer.60 The Infectious Disease Society of America 
recently recommended screening all HIV-positive MSM for anal cancer with anal Pap tests.24  
 Studies of anal cancer screening behavior among MSM have focused almost exclusively 
on men’s acceptance of physician-collected Pap tests.25,27,32 Self-collected anal Paps have been 
shown to have accuracy similar to clinician-collected tests.61,62 Studies of self-tests for HIV and 
other sexually transmitted diseases have found high rates of acceptability among MSM, and it is 
possible that allowing men to use a self-test for anal cancer would increase screening uptake.40-42 
The purpose of the present study was to examine gay and bisexual men’s willingness to use a 
self-collected anal cancer screening test at home and to identify correlates of willingness to use a 
self-test. Findings could help inform future programs for promoting anal cancer screening among 
this higher-risk population 
 
Methods 
I used data from two separate research studies of gay and bisexual men. The studies are 
described in detail elsewhere and briefly here.63-65 
 
Study I 
Sample and procedures. The sample for Study I came from an existing, national panel of 
US households maintained by Knowledge Networks (Palo Alto, CA) Panel members were 
recruited using list-assisted random-digit dialing. Panel members received free Internet access or 
small cash payments in exchange for completing multiple online surveys each month. Study I 
was limited to men aged 18-59 and oversampled for self-identified gay and bisexual men. Of the 
874 eligible panel members invited to participate, 609 (70%) completed the survey in January 
2009. Of those who completed the survey, 306 men self-identified as gay (n = 236) or bisexual 
(n = 70) and were included in the current analysis. The Institutional Review Board at the 
University of North Carolina approved this study. 
Measures. The Study I survey is available online at www.unc.edu/~ntbrewer/hpv.htm. 
Brewer et al. developed the survey items based on their previous work on HPV-related 
diseases.66-68 They cognitively tested the survey to refine item design with 28 gay and bisexual 
men and performed a second round of testing with 8 additional men prior to beginning the study.   
My primary outcome was willingness to self-administer an anal cancer screening test at 
home. Introductory text to the section on anal cancer screening read, “Doctors can use an anal 
Pap test to identify anal cancer. An anal Pap test is when a doctor collects cells from the anus 
using a swab (like an extra long Q-tip) and examines them for changes. An anal Pap test is not 
the same as a test for anal gonorrhea, a colonoscopy, or a digital rectal exam.” The survey 
assessed willingness to get a physician-collected anal Pap test under two conditions: (1) if it were 
free and (2) if it cost $150 out of pocket.  Then the survey assessed willingness to self-administer 
an anal cancer screening test:  “How willing would you be to use an anal swab on yourself to 
screen for anal cancer? You would do this test at home by yourself instead of going to a doctor’s 
office.” Response options for willingness items were definitely wouldn’t, probably wouldn’t, not 
sure, probably would, and definitely would. I collapsed responses into two categories: willing 
(probably or definitely would) and not willing (all other responses).  
The survey assessed participants’ awareness of HPV prior to the study and knowledge of 
HPV using five factual items. I coded three to five correct responses as high HPV knowledge 
and the rest as low HPV knowledge, based on the median number of correct responses for the 
entire sample. The survey also measured respondents’ perceived knowledge of several HPV-
related diseases (genital warts, oral cancer, and anal cancer), as well their worry about the 
disease, perceived likelihood of developing it, and belief that having the disease would change 
their lives. Because pilot testing showed men had low familiarity with HPV-related disease, I 
included brief informative statements about each disease prior to asking questions about them. 
Brewer et al. measured several demographic and health-related characteristics as 
potential covariates.  For urbanicity, they defined “urban” as living in a metropolitan statistical 
area based on zip code.69 The survey also asked about history of sexually transmitted infections, 
genital warts, lifetime number of sexual partners, number of partners in the past year, and 
whether participants had disclosed sexual behavior with men to their physician. 
 
Study II 
Sample and procedures. The Study II sample was drawn from the Harris Interactive 
LGBT Panel, a subset of the Harris Poll Online Panel (Rochester, NY). The Harris Poll Online 
Panel is a voluntary research panel that includes members throughout the entire country; US 
participants are similar to the general population for several demographic characteristics.70 Panel 
members complete multiple surveys each month and receive points that can be exchanged for 
rewards. Eligibility criteria for Study II included being age 18-26 (because the primary focus of 
the study was on HPV vaccination among young adults), living in the US, and self-identifying as 
lesbian, gay, bisexual or transgender. Of 2,014 panel members eligible for the study, 1,005 
(50%) consented to and completed an online survey in October or November 2013. Of those who 
completed the survey, the 428 men who self-identified as gay (n = 309) or bisexual (n =119) 
were included in the current analysis. The Institutional Review Board at The Ohio State 
University approved the current study. 
Measures. Reiter et al. based the Study II survey on the survey used for Study I, as well 
as subsequent surveys on HPV vaccination.71-74 My primary outcome was willingness to self-
administer an anal cancer screening test at home. The survey item read, “There is also a home 
test that may help screen for anal cancer. This test would involve using a swab (like a Q-tip) to 
get an anal specimen. You would do this test at home by yourself instead of going to a doctor’s 
office. How willing would you be to use an anal swab on yourself to screen for anal cancer?” As 
with Study I, the five response options were collapsed into willing to self-test (probably or 
definitely willing) and not willing (note sure, probably or definitely not willing). An additional 
item asked participants to select potential concerns they had about using a home test for anal 
cancer from a list of predefined response options. 
The survey assessed participants’ awareness of HPV prior to the study and knowledge of 
HPV using five factual items. I coded four or five correct responses as high HPV knowledge and 
less than four correct responses as low HPV knowledge, based on the median number correct for 
the entire sample. The survey also measured respondents’ worry about and perceived seriousness 
of HPV-related disease, as well as their perceived likelihood of developing specific diseases 
(genital warts, oral cancer, and anal cancer). 
Reiter et al. measured several demographic and health-related characteristics as potential 
covariates.  For urbanicity, they defined “urban” as self-report of living in an urban or suburban 
area. The survey also asked about history of sexually transmitted infections, genital warts, 
lifetime number of sexual partners, number of partners in the past year, and whether participants 
had disclosed their sexual orientation to their physician. 
 Analyses 
I analyzed data from the two studies separately given their different samples. I used 
logistic regression to identify bivariate correlates of willingness to self-administer an anal cancer 
screening test. I entered statistically significant (p < .05) bivariate correlates into multivariate 
logistic regression models for each study.  
I used McNemar’s test to compare Study I participants’ willingness to self-administer an 
anal cancer screening test to their willingness to get a physician collected anal cancer screening 
test that cost $150 or was free. I used Pearson’s chi-squared test to compare the two study 
samples’ willingness to self-administer the test. 
I analyzed data with Stata release 13 (StataCorp LP, College Station, TX). All statistical 
tests were 2-tailed, using a critical α = 0.05. 
 
Results 
Participant Characteristics 
Most men in Study I identified as gay (77%) and were HIV-negative (83%) (Table 1). 
Their median age was 47 years (range 20-59), and 96% were older than 26. Most were non-
Hispanic White (81%), had a college degree (56%), were insured (86%), and lived in an urban 
area (93%).  Only 23% had ever heard of an anal Pap before the survey, and 14% reported 
having had an anal Pap in the past. 
 Most men in Study II identified as gay (72%), and almost all were HIV negative (96%). 
Their mean age was 23 years (range 18-26). Most identified as non-Hispanic White (64%), had 
health insurance (80%), and lived in an urban area (84%).  Fewer than half had a college degree 
(47%). 
 
Willingness to Self-Administer an Anal Cancer Screening Test 
 Most men in Study I (78%; 95% confidence interval [CI] 73%, 82%) were willing to self-
administer an anal cancer screening test at home. Men were somewhat less willing to self-
administer the test than to get a free physician-collected test (78% vs. 83%; χ2 = 4.41; p = .04).  
They were much more willing to self-administer the test than to get a physician-collected test 
that cost $150 (78% vs. 31%; χ2 = 129.60, p < .001).   
 Two-thirds of Study II men (67%; 95% CI 62%, 71%) were willing to self-administer an 
anal cancer screening test at home, a lower percentage than among Study I participants (p < 
.001). The most common concerns about self-administrating the test that participants cited were 
“I might not do the test right” (61%) and “the test might not be accurate” (59%) (Figure 1). 
About 29% of the men said they would rather go to a doctor to get screened for anal cancer, 22% 
were concerned the test would hurt, and 17% thought it would be embarrassing.  
 
Correlates of Willingness 
 In Study I, men’s willingness to self-administer an anal cancer test was higher if they 
believed MSM should be screened between one and three years (87%) rather than screening at 
other intervals (adjusted odds ratio [aOR] = 2.19; 95% CI 1.17, 4.10) in multivariate analysis 
(Table 2). Willingness was also higher among men who agreed more with the statement: “If I got 
regular anal pap tests, I would trust them to find anal cancer when it is still treatable” (aOR = 
1.47; 95% CI 1.04, 2.09). Additional correlates of willingness in bivariate analysis were higher 
worry about anal cancer, higher knowledge about HPV, belief that HIV affects a man’s chances 
of getting anal cancer, being HIV-positive, and being non-Hispanic white when compared to 
“other” race/ethnicity (all p < .05). 
In Study II, willingness to self-administer an anal cancer screening test was higher among 
men who had higher perceived likelihood of developing anal cancer (aOR = 1.57; 95% CI 1.12, 
2.20) in multivariate analysis (Table 3). In bivariate analyses, correlates of willingness to use a 
self-test were higher worry about diseases caused by HPV, higher knowledge of HPV, having 
five or more lifetime sexual partners, having a college degree, and being older (all p < .05). 
 
Discussion 
 In the two national samples, most gay and bisexual were willing to self-administer an 
anal cancer screening test at home. The proportion of men willing to use a self-collected test was 
similar to or higher than those previously reported for physician-collected Pap tests.27,31,63 The 
possibility that men may prefer a self-collected home test over one performed by a physician is 
supported by my findings that Study I men were more willing to use the self-collected test than 
to get a physician-collected Pap that cost $150 and that fewer than a third of Study II participants 
stated a preference for a physician-collected test. Of note, I found much greater willingness to 
use a self-collected anal cancer screening test than a previous study of acceptability among 
MSM. Gilbert et al. reported only 35% of men were willing to use a self-collected test, but their 
sample was limited to men attending MSM-frequented venues and the test was collected in 
venue bathrooms.28 The increased privacy, comfort, and safety of collecting the test at home may 
be an important component of men’s willingness to self-administer anal cancer screening. This 
relationship has been suggested previously by focus groups and studies of the acceptability of 
HIV self-testing.35,75 
 I identified three potentially modifiable correlates of willingness to use self-collected 
testing in my multivariate analyses. Men in Study II who perceived they had a higher likelihood 
of anal cancer were more willing to self-administer an anal cancer screening test. Reed et al. 
previously identified this association in their analysis of willingness to get a physician-collected 
Pap test.63 Multiple health behavior studies have established that risk perceptions, including 
perceived likelihood, are important predictors of cancer screening participation and other health 
protective actions.44,76,77 This study extends that link to the use of self-administered cancer 
screening tests.  
 Men’s willingness to use a self-collected test in Study I was associated with their trust in 
anal Paps to find cancer when it is still treatable. Belief in the efficacy or benefits of screening is 
another construct frequently correlated with participation in cancer screening programs.78,79 
However, Reed et al. did not find a statistically significant association between perceived test 
efficacy and willingness to get a physician-collected Pap.32 Similarly, in a survey of HIV-
positive and HIV-negative MSM enrolled in the Multicenter AIDS Cohort Study, D’Souza et al. 
found that belief in the utility of anal Pap tests was associated with acceptance of a free test in 
bivariate analyses, but the association was not significant in their multivariate model.27 It is 
possible that test effectiveness is more important to men when considering a home-based test, as 
a test performed by a physician may be assumed to have some minimal level of effectiveness. 
This idea is supported by qualitative work showing some people worry that home-based STI tests 
are less accurate and my own findings that the majority of men in Study II had concerns about 
the self-collected test’s accuracy and their ability to perform it correctly.80 
 The association between believing that MSM should get an anal Pap test to screen for 
anal cancer and men’s willingness to use a self-collected test may simply show that men who 
thought MSM need to be screened were themselves more willing to be screened. Perceived 
norms about engaging in health-promoting behavior have been linked to medication adherence, 
weight loss efforts, and adherence to cancer screening recommendations.81-83 My study shows 
that this relationship could also be true for anal cancer screening, and it should be explored 
further in future research. 
 The strengths of this study were its use of two large, national samples with high 
participation rates.  To my knowledge, this was the first study to explore gay and bisexual men’s 
willingness to self-administer an anal cancer screening test using a national sample. 
 Limitations include the cross-sectional designs and reliance on self-report for the 
measures, including HIV status and screening history. Study sampling was based on sexual 
identity rather than behavior, and thus may not be representative of all MSM. Furthermore, as 
most men lived in urban areas, had health insurance, and were non-Hispanic White, the 
generalizability of my findings to other MSM remains to be established. Currently, no self-
administered anal cancer screening test is licensed for home use outside of research settings. My 
findings for willingness may overestimate men’s actual use should such a test become available. 
Future studies should therefore examine use if a self-administered home test becomes available. 
 In conclusion, the majority of gay and bisexual men were willing to self-administer an 
anal cancer screening test at home. If anal Pap tests are shown to be an effective means of 
reducing incidence and mortality from invasive cancer, allowing men the option of home testing 
could improve screening uptake. This study identified three potentially modifiable factors 
associated with willingness to use a self-test and potential concerns men have with using a self-
test that could be targeted in future public health campaigns to increase screening rates
Tables 1. Participant Characteristics 
 
Study I (n=306) 
No. (%) 
Study II (n=428) 
No. (%) 
Sexual orientation 
   Gay 
 
236 (77) 
 
309 (72) 
   Bisexual 70 (23) 119 (28) 
Race/ethnicity 
   Non-Hispanic White 
 
247 (81) 
 
273 (64) 
   Non-Hispanic Black 14 (5) 28 (7) 
   Hispanic 29 (9) 79 (18) 
   Other 16 (5) 48 (11) 
Age, mean (range, median) 46 (20-59,47) 23 (18-26, 23) 
Annual household income 
   ≥$50,000 
 
204 (67) 
 
151 (35) 
   <$50,000 102 (33) 231 (54) 
   Prefer not to answer -- 46 (11) 
Education 
   Less than college degree 
 
136 (44) 
 
228 (53) 
   College degree or higher 170 (56) 200 (47) 
Health insurance 
   No 
 
44 (14) 
 
86 (20) 
   Yes 262 (86) 342 (80) 
Reside in urban area 
   No 
 
20 (7) 
 
67 (16) 
   Yes 286 (93) 361 (84) 
Relationship status 
   Unmarried or not living with partner 
 
160 (52) 
 
357 (83) 
   Married or living with partner 146 (48) 71 (17) 
HIV status 
   Negative 
 
255 (83) 
 
410 (96) 
   Positive 51 (17) 18 (4) 
Number of lifetime sexual partners 
   0 - 4 
 
35 (11) 
 
202 (47) 
   5 or more 271 (89) 226 (53) 
 
 
 
 
Table 2. Study I Correlates of Willingness to Self-Administer an Anal Cancer Screening Test 
 
No. Willing/Total No. (%)  Bivariate OR (95% CI) 
Adjusted  
OR (95% CI) 
HPV, Anal Cancer, and Screening 
Perceived knowledge of anal cancer1  1.24 (0.84, 1.83) -- 
Worry about anal cancer2  1.68 (1.07, 2.66)* 1.54 (0.94, 2.52) 
Perceived severity of anal cancer2  1.25 (0.89, 1.75) -- 
Perceived likelihood of anal cancer3  1.32 (0.86, 2.02) -- 
Belief that HIV status affects chances of 
    getting anal cancer4 
 2.50 (1.23, 5.07)* 1.95 (0.87, 4.40) 
Trust in anal Pap to find treatable cancer5  1.74 (1.27, 2.40)** 1.47 (1.04, 2.09)* 
Belief that only people who have anal sex  
   need anal Pap tests5 
 1.18 (0.93, 1.50) -- 
Awareness of HPV6 
   Unaware 
 
44/63 (70) 
 
1.00 
 
1.00 
   Aware, low knowledge 98/127 (77) 1.46 (0.74, 2.88) 1.25 (0.59, 2.67) 
   Aware, high knowledge 97/116 (84) 2.20 (1.06, 4.57)* 1.46 (0.65, 3.26) 
Aware of anal pap test    
   No  178/235 (76) 1.00 -- 
   Yes 61/71 (86) 1.95 (0.94, 4.06)  
Ever had an anal Pap test 
   No 
   Yes 
 
203/262 (77) 
36/44 (82) 
 
1.00 
1.31 (0.58, 2.97) 
 
-- 
Belief that doctors recommend anal Pap   
   tests for MSM 
   No 
 
 
48/60 (80) 
 
 
1.00 
 
 
-- 
   Yes 95/112 (85) 1.40 (0.62, 3.16)  
   Don’t know 96/134 (72) 0.63 (0.30, 1.32)  
Believed anal cancer screening should  
   happen every 1-3 y among MSM 
   No 
 
 
115/163 (71) 
 
 
1.00 
 
 
1.00 
   Yes 124/143 (87) 2.72 (1.51, 4.91)** 2.19 (1.17, 4.10)* 
History of digital rectal exam 
  No or don’t know 
 
57/79 (72) 
 
1.00 
 
-- 
  Yes 182/227 (80) 1.56 (0.87, 2.82)  
Sexual History    
Disclosed sex with men to PCP 
   Yes 
 
151/186 (81) 
 
1.00 
 
1.00 
   n/a or missing 26/39 (67) 0.46 (0.22, 0.99)* 0.73 (0.31, 1.69) 
   No 62/81 (77) 0.76 (0.40, 1.42) 1.05 (0.52, 2.10) 
Age at first sexual intercourse (oral, anal, 
   or vaginal) 
   <16 
 
 
88/108 (81) 
 
 
1.00 
 
 
-- 
   ≥16 151/198 (76) 0.73 (0.41, 1.31)  
Number of lifetime sexual partners 
   ≤4 
 
24/35 (69) 
 
1.00 
 
-- 
   ≥5 215/271 (79) 1.76 (0.81, 3.81)  
History of cancer (oral, anal, penile) or 
   lesions (anal, penile) 
   No 
 
 
234/301 (78) 
 
 
1.00 
 
 
-- 
   Yes 5/5 (100) --  
History of genital warts 
   No 
 
204/263 (78) 
 
1.00 
 
-- 
   Yes 35/43 (81) 1.27 (0.56, 2.88)  
HIV status 
   Negative 
 
193/255 (76) 
 
1.00 
 
1.00 
   Positive 46/51 (90) 2.96 (1.12, 7.77)* 2.25 (0.80, 6.34) 
History of sexually transmitted disease 
other 
   than HIV 
   No 
 
 
169/221 (76) 
 
 
1.00 
 
 
-- 
   Yes 70/85 (82) 1.44 (0.76, 2.72)  
Demographic Characteristics  
Sexual orientation    
   Gay 190/236 (81) 1.00 -- 
   Bisexual 49/70 (70) 0.56 (0.31, 1.03)  
Health insurance 
   No 
 
32/44 (73) 
 
1.00 
 
-- 
   Yes 207/262 (79) 1.41 (0.68, 2.92)  
Current smoker 
   No 
 
169/219 (77) 
 
1.00 
 
-- 
   Yes 70/87 (80) 1.22 (0.66, 2.26)  
Race/ethnicity 
   Non-Hispanic White 
 
197/247 (80) 
 
1.00 
 
1.00 
   Non-Hispanic Black 11/14 (79) 0.93 (0.25, 3.46) 0.59 (0.13, 2.61) 
   Hispanic 22/29 (76) 0.80 (0.32, 1.97) 0.94 (0.35, 2.48) 
   Other 9/16 (56) 0.33 (0.12, 0.92)* 0.42 (0.14, 1.31) 
Age,  mean y (s.d.) 46.60 (8.44) 1.01 (0.98, 1.04) -- 
Annual income 
   <$50,000 
 
73/102 (72) 
 
1.00 
 
-- 
   ≥$50,000 166/204 (81) 1.74 (1.00, 3.03)  
Education 
   No college degree 
 
102/136 (75) 
 
1.00 
 
-- 
   College degree 137/170 (81) 1.38 (0.80, 2.38)  
Reside in urban area 
   No 
 
17/20 (85) 
 
1.00 
 
-- 
   Yes 222/286 (78) 0.61 (0.17, 2.15)  
Relationship status 
   Unmarried or not living with partner 
 
122/160 (76) 
 
1.00 
 
-- 
   Married or living with partner 117/146 (80) 1.26 (0.73, 2.17)  
*p < .05   **p ≤ .001 
HPV = human papillomavirus MSM = men who have sex with men  PCP = primary care provider 
1 4-point response scale, from nothing at all (coded as 1) to quite a lot (coded as 4) 
2 4-point scale, from not at all (coded as 1) to quite a lot (coded as 4) 
3 5-point scale, from no chance (coded as 1) to certain (coded as 5) 
4 3-point scale, decreases chances (coded as 1), has no effect (coded as 2), or increases chances (coded as 3) 
5 5-point scale, from strongly disagree (coded as 1) to strongly agree (coded as 5)  
6Cutoff for high-knowledge was ≥3/5 HPV knowledge items correct, based on median # correct for entire study
Table 3. Study II Correlates of Willingness to Self-Administer an Anal Cancer Screening Test 
 
No. Willing/Total No. (%)  Bivariate OR (95% CI) 
Adjusted  
OR (95% CI) 
HPV, Anal Cancer, and Screening   
Worry about diseases  
   caused by HPV1 
 1.36 (1.06, 1.74)* 1.03 (0.78, 1.35) 
Perceived severity of  
   disease caused by HPV2 
 1.09 (0.82, 1.45) -- 
Perceived likelihood of  
   anal cancer3 
 1.69 (1.22, 2.33)** 1.57 (1.12, 2.20)* 
Awareness of HPV4 
   Unaware 
 
33/59 (56) 
 
1.00 
 
1.00 
   Aware, low knowledge 138/221 (62) 1.31 (0.73, 2.34) 1.09 (0.59, 1.99) 
   Aware, high knowledge 114/148 (77) 2.64 (1.39, 5.01)* 1.94 (0.98, 3.85) 
Vaccinated for HPV 
   No 
 
245/372 (66) 
 
1.00 
 
-- 
   Yes 40/56 (71) 1.30 (0.70, 2.40)  
Sexual History    
Disclosed sexual orientation to PCP 
   Yes 
 
98/136 (72) 
 
1.00 
 
-- 
   Somewhat 17/27 (63) 0.66 (0.28, 1.57)  
   No 170/265 (64) 0.69 (0.44, 1.09)  
Age at first sexual intercourse (oral, anal, 
or vaginal) 
   <16 
 
 
68/102 (67) 
 
 
1.00 
 
 
-- 
   ≥16 217/326 (67) 0.99 (0.62, 1.60)  
Number of lifetime sexual partners 
   0 – 4 
 
120/202 (59) 
 
1.00 
 
1.00 
   5 or more 165/226 (73) 1.85 (1.23, 2.77)* 1.42 (0.90, 2.23) 
History of genital warts 
   No 
 
268/408 (66) 
 
1.00 
 
-- 
   Yes 17/20 (85) 2.96 (0.85, 10.27)  
HIV status 
   Negative 
 
272/410 (66) 
 
1.00 
 
-- 
   Positive 13/18 (72) 1.32 (0.46, 3.78)  
History of sexually transmitted disease 
other than HIV 
   No 
 
 
256/386 (66) 
 
 
1.00 
 
 
-- 
   Yes 29/42 (69) 1.13 (0.57, 2.25)  
History of HPV infection 
   No 
 
267/406 (66) 
 
1.00 
 
-- 
   Yes 18/22 (82) 2.34 (0.78, 7.06)  
Demographic Characteristics   
Sexual orientation 
   Gay 
 
217/309 (70) 
 
1.00 
 
1.00 
   Bisexual 68/119 (57) 0.57 (0.37, 0.88)* 0.69 (0.43, 1.10) 
Health insurance 
   No 
 
53/86 (62) 
 
1.00 
 
-- 
   Yes 232/342 (68) 1.31 (0.80, 2.14)  
Race/ethnicity 
   Non-Hispanic White 
 
182/273 (67) 
 
1.00 
 
-- 
   Non-Hispanic Black 20/28 (71) 1.25 (0.53, 2.95)  
   Hispanic 47/79 (59) 0.73 (0.44, 1.23)  
   Other 36/48 (75) 1.50 (0.74, 3.02)  
Age, mean y (s.d.) 23.07 (2.40) 1.11 (1.02, 1.20)* 1.04 (0.94, 1.15) 
Annual income 
   <$50,000 
 
151/231 (65) 
 
1.00 
 
-- 
   ≥$50,000 107/151 (71) 1.29 (0.83, 2.01)  
   Not reported 27/46 (59) 0.75 (0.39, 1.44)  
Education 
   No college degree 
 
139/228 (61) 
 
1.00 
 
1.00 
   College degree 146/200 (73) 1.73 (1.15, 2.61)* 1.36 (0.83, 2.24) 
Reside in urban area 
   No 
 
45/67 (67) 
 
1.00 
 
-- 
   Yes 240/361 (66) 0.97 (0.56, 1.69)  
Relationship status 
   Unmarried or not living with partner 
 
231/357 (65) 
 
1.00 
 
-- 
   Married or living with partner 54/71 (76) 1.73 (0.96, 3.12)  
*p < .05   ** p ≤ .001 
HPV = human papillomavirus PCP = primary care provider 
1 4-point scale, from not at all (coded as 1) to quite a lot (coded as 4) 
2 4-point scale, from not at all (coded as 1) to very (coded as 4) 
3 4-point scale, from no chance (coded as 1) to high chance (coded as 4) 
4 Cutoff for high-knowledge was ≥4/5 HPV knowledge items correct, based on median # correct for entire study
Figure 1. Study II Concerns About Self-Administering an Anal Cancer Screening Test at 
Home 
 
Error bars show 95% confidence intervals. 
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